The UK and US have forged a major bilateral deal that will preserve no tariffs on British pharmaceutical exports entering the US market.
Key Provisions of the Accord
As part of the deal, the UK has committed to boost funding on drugs through the NHS. This pledge secures that tariffs on these vital goods will stay at nothing for a timeframe of the next three years.
This agreement comes after previous threats to hike duties on branded drug products, with potential rates mentioned as high as 100%.
"This agreement with the Britain reinforces the international landscape for new treatments and establishes much-needed balance to American-British drug exports," a statement said.
Trade Impact
Drugs represent one of the Britain's most significant export categories to the United States, which is by far the biggest destination for major British pharmaceutical firms.
Trade data reveal that in the 12 months leading up to last September, the UK sold medicines totaling £11.1bn to the US. This amount made up a significant portion of total UK exports in that timeframe.
"This guarantee safeguards jobs, boosts investment and facilitates the UK to become a worldwide center for life sciences," the Business and Trade Secretary commented.
Key NHS Changes
The pact involves several notable commitments from the British government:
- Price Threshold Increase: The UK will raise the affordability limit at which it judges new medicines to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a goal to raise overall NHS spending on treatments from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Refund Ceiling: The amount drug companies must pay back to the NHS to stay within budget will be limited at 15%. In the past, rebates exceeded 20%.
Industry Background
The deal takes place against a ongoing dispute between the sector and the UK government over drug pricing and regulatory access.
The disagreement were exacerbated by arguments that American customers were paying significantly more for the equivalent treatments than patients in the other developed nations.
Over the last 18 months, several major drug company projects in the UK have been halted or abandoned, while substantial funding commitments have been pledged toward American operations.
A senior figure stated that the NHS needed to invest a greater share on medicines, noting that its expenditure on drugs had decreased as a proportion of its total funding over the past decade.
